Finch Therapeutics Group Stock

Finch Therapeutics Group is a microbiome therapeutics company, develops microbial therapies serving patients with serious.

Sign up today and learn more about Finch Therapeutics Group Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

Invest Now Sell Shares

About Finch Therapeutics Group Stock

Finch Therapeutics, a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch uses machine- learning algorithms informed by high-throughput molecular data to reverse engineer successful clinical experience with fecal transplantation.

Funding History

December 2016	$5.6M
March 2018	$36.0M

Management

CEO

MARK SMITH

CFO

Greg Perry

CMO

KIRK TAYLOR

Trending Companies

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Why EquityZen?

EquityZen helps investors to access private companies and their employees to sell shares.

Join Now

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.

EquityZen Inc. was awarded a 2023 Fintech Breakthrough Award by Tech Breakthrough LLC on or about March 23, 2023, based on the prior calendar year and covering calendar year 2023, and has compensated Tech Breakthrough LLC for use of its name and logo in connection with the award. Tech Breakthrough LLC is a third party and has no affiliation with EquityZen.

EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.
EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
© 2024 EquityZen Inc. All rights reserved.